Sotera Health Company (SHC)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 2
Do Nothing: SHC scores 2/5 — price 16.27 is below the SMA20/50/200 (17.52/18.11/16.92) and EMA9/21 with MACD -0.55 below its -0.36 signal and ADX 22.9 rising against that stack (strengthening downtrend, bounce-only off 15.65); no pullback/oversold limit qualifies (countertrend limit: price < SMA50 with MACD < 0) and no breakout stop qualifies (buy-stop above the settled 16.83 high gives R/R 1.31 < 1.5).
Company overview
Sotera Health Company, based in Broadview Heights, Ohio, provides sterilization, laboratory testing, and advisory services globally. Its services include gamma and electron beam irradiation, ethylene oxide processing, and microbiological and analytical chemistry analyses through its Nelson Labs division. The company serves medical device manufacturers, pharmaceutical companies, and other industries.
Fundamental
fairSotera Health shows strong margins and improving cash flow, but legal risks elevate its risk profile.
Sotera Health pairs ~54% gross margins, ~51% LTM Adjusted EBITDA margins and a deleveraging balance sheet (net leverage 2.9x, no funded maturities before 2031, $412M cash plus a $592M undrawn revolver) with an unresolved ethylene-oxide litigation overhang - roughly 170 California claims heading to trial in 2027, about 550 Georgia personal-injury claims, no reserves and no EO insurance - that links to a debt default trigger if an unstayed judgment tops about $163M. Revenue is compounding mid-to-high single digits, interest expense is falling and FY2026 guidance was reaffirmed, but the stock trades at a fair rather than cheap multiple and the legal tail keeps the risk profile elevated. Verdict: watchlist-quality infrastructure franchise, not a clean entry.
Sentiment
fairSentiment is modestly positive post-earnings, but target revisions and legal overhangs temper enthusiasm.
The catalyst spine is the 2026-11-03 Q3 2026 print — a market-rewarded beat (revenue +4.4% to $324.9M, adjusted EPS $0.29 vs roughly $0.26-0.27, FY26 outlook reaffirmed, Moody's upgrade, stock +12.9%) that is eight days old and only partially priced — set against post-print sell-side target trims (Argus to $15, below the $16.27 spot; Barclays $22 to $20). The sentiment delta is determinate and modestly positive on dense two-window coverage (baseline polarity_score about +0.09 rising to about +0.23 in the scoring window), retail is indeterminate on a Reddit 403 access block, the legal screen shows no regulator-confirmed action in 90 days (no severe flag), and the moderate conflicting-catalyst-signals cap applies with no forward-dated catalyst inside the 30-day horizon.
Technical
weakThe stock is in a downtrend with price below key moving averages and no bullish entry signals.
Chart scores 2/5 (mostly weak/bearish, bounce-only). SHC closed 2026-11-10 at 16.27 below SMA20 17.52, SMA50 18.11, SMA200 16.92, EMA9 16.72, EMA21 17.32, WMA9 16.43, WMA21 17.22, DEMA14 16.36 and daily VWAP 16.37; only TEMA14 16.05 sits below price. MACD line -0.55 is below its -0.36 signal with histogram -0.19, RSI14 35.94 (recovering from 27.07 on 2026-11-03) and Williams %R -81.27 show a stretched but not reversing tape, and ADX14 22.94 rising against a price under the entire MA stack reads as a strengthening DOWN trend rather than accumulation. Volume is distributional: the -6.4% 2026-11-03 session traded 5.36M shares and 2026-11-04 4.61M, versus 2.87M on the 2026-11-09 bounce and 2.01M on 2026-11-10. The only constructive feature is a three-session higher-low base (15.65 -> 16.04 -> 16.02), which is a bounce attempt inside a downtrend, not a trend-aligned bullish setup.
You’re looking at 2026-11-11 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

